Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Durvalumab · Imfinzi, MEDI-4736

Monoclonal antibody · Antagonist of PD-L1 (CD274) · developed by Astrazeneca Uk

Approved FDA, May 2017
AZN Developer
2 Registered trials

What is Durvalumab?

Durvalumab is a human IgG1κ monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1 and CD80, releasing inhibition of T-cell activation and immune responses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Imfinzi, MEDI-4736
Drug type
Monoclonal antibody
Targets
PD-L1 (CD274), PD-1 (PDCD1) (binding partner it blocks), CD80 (binding partner it blocks)
Mechanism
Antagonist of PD-L1 (CD274)
Pathways
T-cell activation, immune response
Therapy area
Oncology
Developer
Astrazeneca Uk Ltd (AZN)
FDA status
Approved as Imfinzi (May 1, 2017), BLA761069 · FDA label
UNII
28X28X9OKV

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 31, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06103864 Phase 3 Breast Cancer Recruiting AZN
NCT03837899 Phase 1/2 Pediatric Cancer Active not recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerHematological MalignanciesPediatric CancerSolid Tumor Pediatric

Other drugs acting on CD274

Acasunlimab Phase 3 AN4005 Phase 1 AXN-2510 Phase 1 CDX-527 Phase 1 Cenopodlin Phase 1 CTX-8371 Phase 1 Enristomig Phase 1 Pumitamig Phase 2/3

More from Astrazeneca Uk

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Durvalumab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.